Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA038497-02
Application #
3962691
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
076580745
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Sharpe, A H; Jaenisch, R (1993) Retroviral spongiform degenerative disease produced by the murine neurotropic retrovirus Cas-Br-E. Dev Biol Stand 80:45-52
Kobayashi, H; Man, S; Graham, C H et al. (1993) Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 90:3294-8
Daley, G Q; Van Etten, R A; Baltimore, D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-30
Teicher, B A; Herman, T S; Holden, S A et al. (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457-61
Van Etten, R A; Jackson, P; Baltimore, D (1989) The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669-78
Stuhlmann, H; Jaenisch, R; Mulligan, R C (1989) Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance. Mol Cell Biol 9:100-8
Stuhlmann, H; Jaenisch, R; Mulligan, R C (1989) Transfer of a mutant dihydrofolate reductase gene into pre- and postimplantation mouse embryos by a replication-competent retrovirus vector. J Virol 63:4857-65
Yang, X M; Martinez, R; Le Beau, J et al. (1989) Evolutionary expression of the neuronal form of the src protein in the brain. Proc Natl Acad Sci U S A 86:4751-5
Jackson, P; Baltimore, D (1989) N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J 8:449-56
Kelley, S L; Basu, A; Teicher, B A et al. (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813-5

Showing the most recent 10 out of 50 publications